{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T06:19:22Z","timestamp":1672813162425},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000022555","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T04:05:11Z","timestamp":1602648311000},"page":"e22555","source":"Crossref","is-referenced-by-count":2,"title":["The incidence risk of programmed cell death-1\/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Mingkai","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuli","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"R1-20230103","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(76)92710-0","article-title":"Doxorubicin\/B.C.N.U. chemotherapy for multiple myeloma in relapse","volume":"1","author":"Alberts","year":"1976","journal-title":"Lancet"},{"key":"R2-20230103","first-page":"216","article-title":"Clinical effects and pharmacokinetics of different dosage schedules of adriamycin","volume":"36","author":"Creasey","year":"1976","journal-title":"Cancer Res"},{"key":"R3-20230103","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/ajd.12835","article-title":"Chemotherapy-induced alopecia: a novel observation","volume":"60","author":"Rossi","year":"2019","journal-title":"Australas J Dermatol"},{"key":"R4-20230103","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol"},{"key":"R5-20230103","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-017-4204-x","article-title":"Chemotherapy-induced irreversible alopecia in early breast cancer patients","volume":"163","author":"Kim","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20230103","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","article-title":"Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer","volume":"4","author":"Matsuda","year":"2018","journal-title":"JAMA Oncol"},{"key":"R7-20230103","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"International Collaborative Ovarian Neoplasm Group","year":"2002","journal-title":"Lancet"},{"key":"R8-20230103","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R9-20230103","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"KEYNOTE-040 investigators Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R10-20230103","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"IMpassion130 trial investigators. atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20230103","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20230103","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20230103","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20230103","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R15-20230103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"R16-20230103","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"R17-20230103","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.cllc.2018.01.004","article-title":"Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study","volume":"19","author":"Hida","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R18-20230103","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R19-20230103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"R20-20230103","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"R21-20230103","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20230103","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R23-20230103","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R24-20230103","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R25-20230103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R26-20230103","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"R27-20230103","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R28-20230103","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R29-20230103","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20230103","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"R31-20230103","doi-asserted-by":"crossref","DOI":"10.5070\/D32412042449","article-title":"PD-1 inhibitor induced alopecia areata","volume":"24","author":"Guidry","year":"2018","journal-title":"Dermatol Online J"},{"key":"R32-20230103","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajco.12838","article-title":"Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis","volume":"14","author":"Man","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"R33-20230103","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R34-20230103","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fonc.2019.00866","article-title":"The association between the incidence risk of peripheral neuropathy and PD-1\/PD-L1 inhibitors in the treatment for solid tumor patients: a systematic review and meta-analysis","volume":"9","author":"Si","year":"2019","journal-title":"Front Oncol"},{"key":"R35-20230103","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group. Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R36-20230103","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R37-20230103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R39-20230103","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R40-20230103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R41-20230103","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"R42-20230103","doi-asserted-by":"crossref","first-page":"e16439","DOI":"10.1097\/MD.0000000000016439","article-title":"The overall safety evaluation of programmed cell death\/programmed cell death ligand 1 (PD-1\/PD-L1) treatment for lung cancer patients: an updated systematic review and meta-analysis","volume":"98","author":"Shang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R43-20230103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"R44-20230103","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"R45-20230103","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"R46-20230103","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): outcomes by programmed death Ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"R47-20230103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T17:00:34Z","timestamp":1672765234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022555"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":46,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022555","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]}}}